By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Luminex reported after the close of the market on Monday that revenues for its fourth quarter increased 8 percent, helped by a 49 percent increase in consumables-related revenues.

For the three months ended Dec. 31, 2010 total revenues for the Austin, Texas-based molecular diagnostics and multiplex instrument firm rose to $41.2 million, compared to $38.2 million a year ago. It beat consensus Wall Street estimates of $38.1 million in revenues for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.